Hepatitis C Virus Therapy in Liver Transplant Recipients: Response Predictors, Effect on Fibrosis Progression, and Importance of the Initial Stage of Fibrosis
Authors:
Open Access
- 24 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (12) , 1766-1777
Abstract
Antiviral therapy after liver transplantation (LT) using interferon (IFN) and ribavirin (RBV) can achieve a sustained virological response (SVR) rate ranging from 20% to 45%. The aims of our study were to assess efficacy and tolerability of therapy, effect on fibrosis progression and the importance of the initial fibrosis stage to outcome. A total of 113 hepatitis C virus (HCV)-infected LT patients received 133 courses of IFN (standard, n = 29, pegylated IFN [pegIFN], n = 104) and RBV (75% genotype 1). Early virological response (EVR), end-of-treatment (EOT), and SVR were obtained in 74%, 55%, and 38%, respectively. EVR, completion of treatment, viral load before therapy, genotype non-1, and use of pegIFN were predictive of SVR, but only EVR remained in the multivariate analysis. SVR was obtained in 45% patients who received a second course of therapy. Paired biopsies at baseline, at EOT and at long-term were available in 42 patients. The mean fibrosis stage remained stable in patients with SVR and increased in patients without response. Rejection episodes were observed in 6% of patients. Tolerability of therapy decrease in patients with fibrosis stage ≥3 on baseline liver biopsy. A total of 20% of them died or were retransplanted due to liver failure as opposed to 1% of patients who had fibrosis stageKeywords
This publication has 35 references indexed in Scilit:
- Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative AnalysisAmerican Journal of Transplantation, 2006
- Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis CLiver Transplantation, 2006
- Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinationJournal of Hepatology, 2004
- Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1Transplantation, 2004
- Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized studyGastroenterology, 2003
- Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis CLiver Transplantation, 2002
- A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis CHepatology, 2002
- Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipientsHepatology, 2002
- European collaborative study on factors influencing outcome after liver transplantation for hepatitis CGastroenterology, 1999
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996